assertion

Full identifier: http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#assertion

Searching for classes... Loading...

Searching for instances... Loading...

Searching for templates... Loading...

Minted in Nanopublication

 RAmIAR0YhB comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAmIAR0YhB...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "cyramza r as a single agent or in combination with paclitaxel for treatment of advanced or metastatic gastric or gastro esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine or platinum containing chemotherapy 1 1 in combination with docetaxel for treatment of metastatic non small cell lung cancer with disease progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving cyramza 1 2 in combination with folfiri for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine 1 3 as a single agent for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of 4 ng ml and have been treated with sorafenib 1 4 cyramza r cyramza in combination with docetaxel is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with disease progression on or after platinum based chemotherapy patients with epidermal growth factor receptor egfr or anaplastic lymphoma kinase alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving cyramza cyramza in combination with folfiri irinotecan folinic acid and fluorouracil is indicated for the treatment of patients with metastatic colorectal cancer mcrc with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAmIAR0YhB... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T14:43:26.175+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAmIAR0YhB... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAmIAR0YhB... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAmIAR0YhB... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAmIAR0YhB...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAmIAR0YhB... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAmIAR0YhB...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 3 Jul 2021, 12:43:26 UTC

References

Loading...

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)